Loading...
XJPX2160
Market cap1.01bUSD
Jan 15, Last price  
3,155.00JPY
1D
0.96%
1Q
6.23%
Jan 2017
334.17%
IPO
1,068.52%
Name

GNI Group Ltd

Chart & Performance

D1W1MN
XJPX:2160 chart
P/E
19.55
P/S
6.08
EPS
161.41
Div Yield, %
0.00%
Shrs. gr., 5y
3.84%
Rev. gr., 5y
38.97%
Revenues
26.01b
+49.32%
273,588,000204,346,000272,876,00090,332,000161,943,000183,600,000474,717,0001,016,670,0001,306,931,0002,648,451,0005,018,944,0007,446,067,0009,773,862,00012,690,246,00017,418,966,00026,010,571,000
Net income
8.09b
P
-1,279,454,000-1,366,385,000-258,088,000-435,450,000-482,255,000-730,776,000-327,953,000-623,150,000-513,101,000-175,206,000192,173,000629,919,0001,258,127,00055,243,000-868,252,0008,094,202,000
CFO
6.55b
+1,565.14%
-1,031,582,000-942,814,000-130,543,000-163,989,000-351,819,000-662,821,000-567,075,000-382,203,000-518,714,000-315,226,000610,230,000788,587,0001,377,519,000552,268,000393,320,0006,549,337,000

Profile

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
URL
https://www.gnipharma.com/
IPO date
Aug 31, 2007
Employees
701
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
26,010,571
49.32%
17,418,966
37.26%
Cost of revenue
21,430,038
19,817,520
Unusual Expense (Income)
NOPBT
4,580,533
(2,398,554)
NOPBT Margin
17.61%
Operating Taxes
3,108,669
1,636,139
Tax Rate
67.87%
NOPAT
1,471,864
(4,034,693)
Net income
8,094,202
-1,032.24%
(868,252)
-1,671.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
760
6,298
BB yield
0.00%
-0.01%
Debt
Debt current
1,949,158
379,611
Long-term debt
2,149,710
495,099
Deferred revenue
(1,174,619)
Other long-term liabilities
15,224,381
9,887,987
Net debt
(23,130,318)
(13,067,238)
Cash flow
Cash from operating activities
6,549,337
393,320
CAPEX
(2,075,977)
(1,939,976)
Cash from investing activities
(6,842,000)
(4,116,163)
Cash from financing activities
10,686,000
(646,327)
FCF
(705,645)
(5,576,417)
Balance
Cash
23,150,512
11,245,853
Long term investments
4,078,674
2,696,095
Excess cash
25,928,657
13,071,000
Stockholders' equity
24,100,982
13,578,337
Invested Capital
30,783,996
15,986,056
ROIC
6.29%
ROCE
8.17%
EV
Common stock shares outstanding
48,891
47,931
Price
2,830.00
103.16%
1,393.00
-5.94%
Market cap
138,360,851
107.23%
66,768,043
-6.64%
EV
117,488,896
52,542,081
EBITDA
5,188,955
(1,876,888)
EV/EBITDA
22.64
Interest
1,250,685
869,887
Interest/NOPBT
27.30%